Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
Shinichiro UedaMichio ShimabukuroOsamu ArasakiKoichi NodeTakashi NomiyamaTakeshi MorimotoPublished in: Cardiovascular drugs and therapy (2019)
Clinicaltrials.gov NCT02330406.